| Mineralocorticoid receptor antagonists and kidney diseases: pathophysiological basis J Barrera-Chimal, S Girerd, F Jaisser Kidney International 96 (2), 302-319, 2019 | 189 | 2019 |
| Spironolactone prevents chronic kidney disease caused by ischemic acute kidney injury J Barrera-Chimal, R Pérez-Villalva, R Rodríguez-Romo, J Reyna, N Uribe, ... Kidney international 83 (1), 93-103, 2013 | 133 | 2013 |
| The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling J Barrera-Chimal, GR Estrela, SM Lechner, S Giraud, S El Moghrabi, ... Kidney International 93 (6), 1344-1355, 2018 | 130 | 2018 |
| Mineralocorticoid receptor antagonists in diabetic kidney disease—Mechanistic and therapeutic effects J Barrera-Chimal, I Lima-Posada, GL Bakris, F Jaisser Nature Reviews Nephrology 18 (1), 56-70, 2022 | 119 | 2022 |
| Pathophysiologic mechanisms in diabetic kidney disease: A focus on current and future therapeutic targets J Barrera‐Chimal, F Jaisser Diabetes, Obesity and Metabolism 22, 16-31, 2020 | 113 | 2020 |
| Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury–mediated chronic kidney disease: role of oxidative stress L Lattenist, SM Lechner, S Messaoudi, A Le Mercier, S El Moghrabi, ... Hypertension 69 (5), 870-878, 2017 | 110 | 2017 |
| AT1 receptor antagonism before ischemia prevents the transition of acute kidney injury to chronic kidney disease R Rodriguez-Romo, K Benitez, J Barrera-Chimal, R Perez-Villalva, ... Kidney International 89 (2), 363-373, 2016 | 93 | 2016 |
| Benefit of mineralocorticoid receptor antagonism in AKI: role of vascular smooth muscle Rac1 J Barrera-Chimal, G André-Grégoire, AN dinh Cat, SM Lechner, J Cau, ... Journal of the American Society of Nephrology 28 (4), 1216-1226, 2017 | 81 | 2017 |
| Hsp72 is an early and sensitive biomarker to detect acute kidney injury J Barrera‐Chimal, R Pérez‐Villalva, C Cortés‐González, ... EMBO molecular medicine 3 (1), 5-20, 2011 | 76 | 2011 |
| Recovery from ischemic acute kidney injury by spironolactone administration K Sánchez-Pozos, J Barrera-Chimal, J Garzón-Muvdi, R Pérez-Villalva, ... Nephrology Dialysis Transplantation 27 (8), 3160-3169, 2012 | 67 | 2012 |
| Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia J Barrera-Chimal, S Prince, F Fadel, S El Moghrabi, DG Warnock, ... Journal of the American Society of Nephrology 27 (2), 398-404, 2016 | 59 | 2016 |
| Proximal renal tubular injury in rats sub-chronically exposed to low fluoride concentrations MC Cárdenas-González, LM Del Razo, J Barrera-Chimal, ... Toxicology and applied pharmacology 272 (3), 888-894, 2013 | 53 | 2013 |
| Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study M Ojeda-Cervantes, J Barrera-Chimal, J Alberú, R Pérez-Villalva, ... American journal of nephrology 37 (5), 481-490, 2013 | 53 | 2013 |
| Are recently reported biomarkers helpful for early and accurate diagnosis of acute kidney injury? J Barrera-Chimal, NA Bobadilla Biomarkers 17 (5), 385-393, 2012 | 52 | 2012 |
| Mild ischemic injury leads to long-term alterations in the kidney: amelioration by spironolactone administration J Barrera-Chimal, R Pérez-Villalva, JA Ortega, A Sánchez, ... International journal of biological sciences 11 (8), 892, 2015 | 48 | 2015 |
| Hsp72 is a novel biomarker to predict acute kidney injury in critically ill patients LE Morales-Buenrostro, OI Salas-Nolasco, J Barrera-Chimal, ... PloS one 9 (10), e109407, 2014 | 46 | 2014 |
| Roles of mineralocorticoid receptors in cardiovascular and cardiorenal diseases J Barrera-Chimal, B Bonnard, F Jaisser Annual Review of Physiology 84, 585-610, 2022 | 42 | 2022 |
| Delayed spironolactone administration prevents the transition from acute kidney injury to chronic kidney disease through improving renal inflammation J Barrera-Chimal, L Rocha, I Amador-Martínez, R Pérez-Villalva, ... Nephrology Dialysis Transplantation 34 (5), 794-801, 2019 | 41 | 2019 |
| Short‐and long‐term administration of the non‐steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome‐related cardio‐renal dysfunction M Lachaux, J Barrera‐Chimal, L Nicol, I Rémy‐Jouet, S Renet, ... Diabetes, Obesity and Metabolism 20 (10), 2399-2407, 2018 | 40 | 2018 |
| The calcium-sensing receptor increases activity of the renal NCC through the WNK4-SPAK pathway S Bazúa-Valenti, L Rojas-Vega, M Castañeda-Bueno, J Barrera-Chimal, ... Journal of the American Society of Nephrology 29 (7), 1838-1848, 2018 | 39 | 2018 |
